Infantile epilepsy encompasses a wide range of seizure disorders that begin in the first year or two of life, and the outcomes vary enormously depending on the specific type. Some forms are self-limiting, with seizures that stop on their own within months and leave no lasting mark on development. Others fall under the umbrella of developmental and epileptic encephalopathies, conditions where the seizures themselves and the underlying brain abnormality combine to impair a child’s cognitive and motor growth. What makes infantile epilepsy especially challenging is that many of these conditions look similar at first, yet require very different treatments, and the window for effective intervention is often narrow.
Why the First Year of Life Is Uniquely Vulnerable
The infant brain is undergoing explosive growth: forming new connections, pruning unnecessary ones, and laying down the myelin insulation that allows nerve signals to travel efficiently. This intense developmental activity makes the brain more susceptible to seizures than at any other stage of life. The immune cells that reside in the brain, called microglia, play a dual role during this period. They help sculpt healthy neural circuits by removing excess connections, but when activated by seizures or inflammation, they release molecules that can damage neurons and promote further seizure activity.
Both inflammation inside the brain and in the rest of the body can disrupt the barriers that normally protect brain tissue, allowing immune cells and inflammatory signals to enter and interfere with developing neural circuits. Research into blocking this inflammatory cascade has shown promising results in animal models, raising the possibility that anti-inflammatory strategies could one day help prevent epilepsy from worsening after early seizures.
The Genetic Revolution in Understanding Causes
Genetics has reshaped the landscape of infantile epilepsy. Over the past two decades, the number of known single-gene causes has grown rapidly, with newly identified mutations in genes that control ion channels, synaptic signaling, brain development, and gene regulation. Many of these mutations arise spontaneously in the child rather than being inherited from a parent. Somatic mosaicism, where only some of the child’s cells carry the mutation, and inherited recessive patterns also occur. Adding to the complexity, several different genes can cause what looks like the same clinical syndrome, and a single gene can produce very different seizure types depending on the specific mutation.
One well-studied example is the SCN1A gene, which encodes a sodium channel critical for the function of inhibitory neurons. Loss-of-function mutations in SCN1A are the primary cause of Dravet syndrome, found in roughly 70 to 80 percent of affected children. Because these mutations cripple the neurons that normally keep brain activity in check, the result is severe, treatment-resistant seizures beginning in the first year of life, along with significant cognitive impairment. Animal studies have confirmed that the core problem is a failure of inhibitory circuits, which explains both the seizures and the cognitive difficulties.
Not all genetic infantile epilepsies are devastating. Mutations in the PRRT2 gene, which encodes a protein involved in synaptic transmission, are the most common cause of a condition called benign familial infantile epilepsy. In one study, PRRT2 mutations were identified in about 82 percent of families with this disorder. These children have focal seizures in infancy that respond well to medication and resolve on their own, typically without any developmental consequences. The same gene can also cause a movement disorder that appears later in childhood, illustrating how a single genetic change can affect the brain differently at different ages.
Newer discoveries continue to expand the list. Mutations in SCN3A, which encodes a different sodium channel that is highly active in the developing brain, have been linked to early infantile epileptic encephalopathy, a finding that also suggested potential drug targets.
When Brain Structure Is the Problem
Not every case of infantile epilepsy traces back to a gene mutation affecting a channel or receptor. Structural brain malformations, especially those involving the cerebral cortex, are a major cause. Disorders where neurons fail to migrate to their proper positions during fetal development carry the highest risk. In one study of newborns with various brain malformations, about a quarter of those with neuronal migration disorders developed epilepsy, a higher rate than any other malformation type.
These structural problems include conditions like lissencephaly, where the brain surface is abnormally smooth rather than folded, and periventricular nodular heterotopia, where clusters of neurons get stranded in the wrong location. Children with isolated lissencephaly often develop infantile spasms along with severe developmental delay. Focal cortical dysplasia, where a patch of cortex develops abnormally, is particularly important because it is sometimes amenable to surgical removal, which can dramatically reduce or eliminate seizures.
Metabolic Causes and Why They Demand Fast Recognition
A subset of infantile seizures stems from inborn errors of metabolism, conditions where the body cannot properly process certain nutrients or biochemical building blocks. These cases deserve special attention because they often do not respond to standard seizure medications but can be controlled with specific treatments targeting the underlying metabolic defect. For example, pyridoxine-dependent epilepsy responds to vitamin B6, and glucose transporter deficiency responds to a ketogenic diet.
A systematic review of neonatal seizures caused by metabolic disorders found that children treated only with conventional seizure medications fared worse neurologically than those who received targeted metabolic treatment early on. The message from the research is consistent: when a metabolic cause is identified quickly, treatment aimed at the underlying disorder can control seizures and prevent the brain damage that accumulates with prolonged, uncontrolled epileptic activity.
Recognizing Specific Syndromes
Clinicians classify infantile epilepsies into recognized syndromes based on the age seizures begin, their appearance, EEG patterns, and the child’s developmental trajectory. The International League Against Epilepsy separates these into two broad camps: self-limited syndromes, where seizures are expected to stop on their own, and developmental and epileptic encephalopathies, where both the cause and the seizure activity contribute to developmental problems.
Infantile Epileptic Spasms Syndrome
Formerly known as West syndrome, infantile epileptic spasms syndrome is one of the most recognizable patterns. Spasms typically appear between three and twelve months of age and consist of brief, sudden contractions of the trunk and limbs, often occurring in clusters shortly after waking. The hallmark EEG pattern, called hypsarrhythmia, shows chaotic, high-voltage activity across the brain. Variations of this pattern exist, and while they are not specific to any one cause, more disorganized patterns tend to indicate more severe disease. Several scoring systems have been developed to help clinicians track how the EEG responds to treatment.
Ohtahara Syndrome
At the severe end of the spectrum, Ohtahara syndrome begins within the first few months of life with frequent tonic spasms that occur during both sleep and waking. The EEG shows a distinctive suppression-burst pattern, where brief bursts of electrical activity alternate with periods of near-silence at regular intervals. Brain imaging reveals structural abnormalities in most cases, often asymmetric malformations. The prognosis is generally poor for motor and cognitive development, and many affected children go on to develop other severe seizure types as they grow.
Dravet Syndrome
Dravet syndrome typically announces itself with prolonged, fever-triggered seizures in a previously healthy infant around six months of age. Over the following months and years, additional seizure types emerge, and developmental progress slows or regresses. As noted earlier, loss-of-function SCN1A mutations underlie the majority of cases. The seizures are notoriously difficult to treat, and certain common medications, particularly sodium channel blockers, can actually worsen seizures in Dravet syndrome, making accurate genetic diagnosis critical.
Self-Limiting Familial Infantile Epilepsy
On the favorable end, self-limiting familial infantile epilepsies are inherited in an autosomal dominant pattern and produce focal motor seizures in otherwise healthy infants. Seizures tend to stop during infancy or early childhood without leaving developmental consequences. When PRRT2 is the underlying gene, sodium channel–blocking medications like oxcarbazepine or carbamazepine are effective, and families have achieved seizure-free status in all treated patients in at least one reported series.
Diagnosis in a Rapidly Evolving Era
The traditional diagnostic workup for infantile epilepsy centers on EEG monitoring, brain MRI, and blood tests for metabolic conditions. EEG remains indispensable for classifying the seizure type and syndrome, and for tracking treatment response. When standard imaging and EEG cannot pinpoint where seizures originate, more invasive methods like stereoelectroencephalography, where electrodes are placed directly into brain tissue, may be used to map the seizure focus before surgery is considered.
Genetic testing has become increasingly central. A multicenter study across four countries evaluated rapid genome sequencing for 100 infants with new-onset epilepsy and achieved a diagnostic yield of 43 percent, meaning nearly half of the infants received a definitive genetic diagnosis. The yield was highest among the sickest babies: 71 percent for those in intensive care, compared with 30 percent for outpatients. The median time from enrollment to results was about three weeks, fast enough to influence treatment decisions during a critical developmental window.
Access to these tools is far from universal. In resource-limited settings, the major barriers to genetic diagnosis include high costs, limited access to specialized laboratories, and a shortage of experts who can interpret the results. This gap means that many children in low- and middle-income countries never receive a precise diagnosis, which in turn limits access to targeted treatments.
Treatment Strategies
Treatment for infantile epilepsy is not one-size-fits-all. It ranges from conventional seizure medications to hormonal therapies, dietary interventions, surgery, and emerging precision approaches.
Hormonal Therapy for Infantile Spasms
For infantile spasms specifically, hormonal treatments are the first-line approach. Adrenocorticotropic hormone (ACTH) injections and high-dose oral steroids like prednisolone have been the standard for decades, with spasm resolution rates around 60 to 70 percent. A persistent question has been whether ACTH is truly superior to oral steroids. A meta-analysis comparing the two found no significant difference in spasm cessation, hypsarrhythmia resolution, relapse rates, or side effects. Given that ACTH is considerably more expensive and requires injections, the evidence increasingly supports high-dose oral prednisolone as a safe and effective alternative.
The Ketogenic Diet
The ketogenic diet, a high-fat, very-low-carbohydrate regimen that shifts the brain’s energy source from glucose to ketone bodies, has a long history in epilepsy treatment and is used in infants with drug-resistant seizures. A meta-analysis of studies in infants estimated that about 59 percent achieved at least a 50 percent reduction in seizures, and roughly a third became seizure-free. The diet is generally safe and tolerable in infants, though it requires careful nutritional monitoring.
A randomized trial in the UK compared the classic ketogenic diet to adding another seizure medication in infants with drug-resistant epilepsy. At eight weeks, the two approaches performed similarly: about 44 percent of infants on the ketogenic diet and 40 percent on medication had a meaningful seizure reduction. Seizure freedom rates were also comparable, at 11 and 13 percent respectively. These results suggest the ketogenic diet is a legitimate alternative rather than a last resort, though it did not clearly outperform medication in this trial.
Epilepsy Surgery in Infants
When seizures arise from a defined region of the brain and do not respond to medication, surgery can be transformative, even in very young children. Hemispheric disconnection procedures, where one half of the brain is surgically isolated from the other, are performed in infants with severe unilateral conditions like hemimegalencephaly or extensive cortical dysplasia. One institutional series of 21 infants who underwent hemispherectomy reported favorable seizure outcomes in 95 percent, with 90 percent achieving the best possible outcome class. In a longer-term follow-up study spanning over twelve years, about two-thirds of children remained seizure-free, and some were eventually able to stop taking medication entirely.
Outcomes depend heavily on the underlying cause. Children with focal cortical dysplasia tend to do better after surgery than those with hemimegalencephaly. When an initial, more limited resection fails to control seizures, proceeding to a full hemispheric disconnection still often leads to good seizure control.
Precision Medicine and Gene-Based Therapies
The rapid identification of genetic causes has opened the door to treatments tailored to a child’s specific mutation. For some conditions, precision medicine means choosing the right conventional medication: a sodium channel blocker for PRRT2-related epilepsy, or avoiding sodium channel blockers in Dravet syndrome. For tuberous sclerosis complex, an mTOR pathway inhibitor called everolimus targets the molecular defect directly. For certain metabolic epilepsies, enzyme replacement or specific cofactors can address the root cause.
The most exciting frontier involves antisense oligonucleotides (ASOs), short pieces of synthetic genetic material designed to adjust the activity of a specific gene at the molecular level. ASOs can silence an overactive mutant gene, boost the output of a healthy copy, or correct errors in how a gene’s instructions are read. In a mouse model of KCNT1-related epilepsy, a single injection of an ASO targeting the mutant gene significantly reduced seizure frequency, improved behavior, and extended survival. A study evaluating which infants with genetic epilepsy might be candidates for ASO therapy found that about 16 percent of those tested carried mutations amenable to existing ASO strategies, with more than half of those suitable for a gene-silencing approach. Clinical trials in humans are underway for several genetic epilepsies.
Neurodevelopmental Consequences
For children with developmental and epileptic encephalopathies, the impact on cognition and behavior extends well beyond the seizures themselves. A longitudinal study found that earlier seizure onset predicted worse adaptive and cognitive function. Longer duration of epilepsy correlated with lower IQ scores, and the number of seizure medications a child required, which serves as a proxy for how difficult the epilepsy was to control, also tracked with poorer outcomes. Perhaps most telling, the degree to which normal background brain rhythms matured over time on EEG was the single strongest predictor of cognitive outcome. Children whose brain activity failed to develop normal age-appropriate patterns had consistently lower IQ scores and weaker adaptive skills.
Episodes of prolonged seizure activity, known as status epilepticus, were associated with worse adaptive performance as well. Children with genetic or unknown causes of early-onset encephalopathy were far more likely to have severe intellectual disability and autistic traits compared to those whose seizures stemmed from structural causes that could be surgically addressed.
Not all outcomes are bleak. A study following adults who had infantile spasms found that about a quarter had normal or near-normal intelligence. Some held professional jobs, married, and had healthy children. These better outcomes were not limited to children with no identifiable cause; even some with symptomatic spasms did well in the long run.
The Toll on Families
The burden of infantile epilepsy falls heavily on caregivers. A literature review examining the impact of developmental and epileptic encephalopathies on families found widespread negative effects on caregivers’ emotional wellbeing, physical health, daily routines, relationships, social lives, and work productivity. When caregivers’ quality of life was measured directly, the results ranged widely, from ideal states to high-needs states. Caregivers most frequently reported struggling with finding time for activities they enjoyed and looking after their own health.
These findings underscore that managing infantile epilepsy is not purely a medical challenge. Families need coordinated support that includes respite care, mental health services, and help navigating the complex web of therapies and specialists involved in their child’s care.
Sudden Unexpected Death in Epilepsy
SUDEP, or sudden unexpected death in epilepsy, is a rare but devastating outcome that affects children as well as adults. The mechanisms are not fully understood but appear to involve a cascade of events including disrupted brain activity, abnormal heart and breathing responses, and brainstem dysfunction. Known risk factors include generalized tonic-clonic seizures, seizures during sleep, and poor medication adherence.
In a national case series of children who died from SUDEP, about 12 percent were under two years old, and genetic causes were the most common underlying etiology, present in over half the cases. A recurring observation was that many children had a recent infection at the time of death, which may have lowered their seizure threshold and triggered a fatal event. This has led some researchers to suggest that periods of illness could warrant heightened monitoring for children at high risk.
Growing Up with Infantile-Onset Epilepsy
Children who survive severe infantile epilepsy face a long road that changes shape over time. Some syndromes evolve: infantile spasms can transition into Lennox-Gastaut syndrome, bringing new seizure types and additional treatment challenges. Dravet syndrome presents shifting problems across childhood and into adulthood, including movement difficulties, behavioral changes, and ongoing seizure management needs. Conditions like tuberous sclerosis complex bring new medical concerns in adulthood, including kidney and lung complications, that pediatric teams may not have anticipated.
The transition from pediatric to adult care is itself a vulnerable period. Many adult neurologists have limited experience with rare childhood-onset epilepsies, and the comprehensive, multidisciplinary care that pediatric centers provide does not always have an equivalent in adult medicine. Families who have spent years building relationships with a child’s care team may find themselves starting over. Planning for this transition ideally begins years before it happens, with detailed medical summaries, gradual introductions to adult providers, and attention to the psychosocial and vocational needs that become central in adolescence and young adulthood.